XML 145 R28.htm IDEA: XBRL DOCUMENT
v3.25.2

Stockholders’ Deficit (Tables) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2025 | Dec. 31, 2024
Stockholders’ Deficit [Abstract] |  |
Schedule of Compensation Expense Related Restricted Stock Awards | The table below summarizes the compensation expense related to the Company’s restricted stock awards for the three months ended March 31:
|  | 2025 |  | 2024
Directors |  |  |  |  |  |
October 1, 2024 – 1,914,580 Directors’ share grant of common stock |  | $ | 326,000 |  | $ | —
February 23, 2023 – 168,419 share grant of common stock |  |  | 14,000 |  |  | 43,000
Employees |  |  |  |  |  |
January 15, 2025 – Captus Management team 4,083,400 restricted stock grant |  |  | 248,000 |  |  | —
December 17, 2024 – VP Energy 500,000 share grant of common stock |  |  | 31,000 |  |  | —
September 30, 2024 – CEO 1,671,682 share grant of common stock |  |  | 136,000 |  |  | —
June 19, 2023 – CFO 675,058 share grant of common stock |  |  | 17,000 |  |  | 165,000
Total |  | $ | 772,000 |  | $ | 208,000
| The table below summarizes the compensation expense related to the Company’s restricted stock awards for the years ended December 31:
|  | 2024 |  | 2023
Directors |  |  |  |  |  |  |
October 1, 2024 – 1,914,580 Directors’ share grant of common stock |  | $ | 623,000 |  | $ | — |
February 23, 2023 – 168,419 share grant of common stock |  |  | 109,000 |  |  | 190,000 |
Consultants |  |  |  |  |  |  |
December 5, 2024 – 58,644 share grant of common stock |  |  | — |  |  | 20,000 |
August 23, 2023 – 48,000 share grant of common stock |  |  | — |  |  | 24,000 |
October 26, 2021 – 17,724 share grant of common stock |  |  | — |  |  | 129,000 |
October 22, 2021 – 8,637 share grant for common stock |  |  | — |  |  | 66,000 |
October 20, 2021 – 17,724 share grant for common stock |  |  | — |  |  | 154,000 |
Employees |  |  |  |  |  |  |
December 17, 2024 – VP Energy 500,000 share grant of common stock |  |  | 5,000 |  |  | — |
September 30, 2024 – CEO 1,671,682 share grant of common stock |  |  | 454,000 |  |  | — |
June 19, 2023 – CFO 675,058 share grant of common stock |  |  | 397,000 |  |  | 530,000 |
April 4, 2022 – CFO 166,667 share grant of common stock |  |  | — |  |  | 395,000 |
Stock-based compensation expense reversal for April 4, 2022 grant |  |  | — |  |  | (1,910,000 | )
Other |  |  |  |  |  |  |
Officer contributed capital |  |  | — |  |  | 250,000 |
|  | $ | 1,588,000 |  | $ | (152,000 | )
Schedule of Service-Based RSUs |
|  | Number of Units |  | Weighted Average Grant-date Per Share Fair Value
Balance as of December 31, 2024 |  | 4,620,511 |  |  | $ | 0.78
Granted |  | 4,083,300 |  |  | $ | 0.45
Issued |  | (844,245 | ) |  | $ | 1.06
Forfeited |  | — |  |  | $ | —
Balance as of March 31, 2025 |  | 7,859,566 |  |  | $ | 0.55
| The following table presents a summary of the activity of the RSUs:
|  | Number of Units |  | Weighted Average Grant-date er Share Fair Value
Balance as of December 31, 2022 |  | — |  |  |  | —
Granted |  | 843,478 |  |  | $ | 1.51
Vested |  | (112,508 | ) |  | $ | 1.40
Forfeited |  | — |  |  | $ | —
Balance as of December 31, 2023 |  | 730,970 |  |  | $ | 1.53
Granted |  | 4,086,261 |  |  | $ | 0.62
Vested |  | (196,720 | ) |  | $ | 1.56
Forfeited |  | — |  |  | $ | —
Balance as of December 31, 2024 |  | 4,620,511 |  |  | $ | 0.73
Schedule of Warrants Transactions | Transactions involving warrants are as follows for the Three months ended March 31, 2025:
|  | Number of Shares |  | Weighted Average Strike Price/Share |  | Weighted Average Remaining Contractual Term (Years) |  | Weighted Average Grant Date Fair Value |  | Weighted Average Intrinsic Value
Outstanding – December 31, 2024 |  | 5,530,198 |  | $ | 0.55 |  | 9.68 |  | $ | 0.55 |  | $ | 0.39
Granted |  | 6,866,856 |  |  | 1.50 |  | 9.79 |  |  | 0.17 |  |  | —
Exercised |  | — |  |  | — |  | — |  |  | — |  |  | —
Expired |  | — |  |  | — |  | — |  |  | — |  |  | —
Outstanding – March 31, 2025 |  | 12,397,054 |  |  | 1.08 |  | 9.69 |  |  | 0.34 |  |  | 0.04
Exercisable – March 31, 2025 |  | 12,397,054 |  |  | 1.08 |  | 9.69 |  |  | 0.34 |  |  | 0.04
Non-exercisable – March 31, 2025 |  | — |  | $ | — |  | — |  | $ | — |  | $ | —
| Transactions involving warrants are as follows for the year ended December 31,:
2024 |  | Number of Shares |  | Weighted Average Strike Price/Share |  | Weighted Average Remaining Contractual Term (Years) |  | Weighted Average Grant Date Fair Value |  | Weighted Average Intrinsic Value
Outstanding – December 31, 2023 |  | 1,844,781 |  |  | $ | 9.84 |  | 0.55 |  | $ | 1.36 |  | $ | —
Granted |  | 5,530,198 |  |  |  | 0.55 |  | 9.68 |  |  | 0.55 |  |  | 0.39
Exercised |  | (165,622 | ) |  |  | 0.006 |  | 0.75 |  |  | 9.06 |  |  | 1.48
Expired |  | (1,679,159 | ) |  |  | 10.98 |  | — |  |  | 7.55 |  |  | —
Outstanding – December 31, 2024 |  | 5,530,198 |  |  |  | 0.55 |  | 9.68 |  |  | 0.55 |  |  | 0.39
Exercisable – December 31, 2024 |  | 5,530,198 |  |  |  | 0.55 |  | 9.68 |  |  | 0.55 |  |  | 0.39
Non-exercisable – December 31, 2024 |  | — |  |  | $ | — |  | — |  | $ | — |  | $ | —
2023 |  | Number of Shares |  | Weighted Average Strike Price/Share |  | Weighted Average Remaining Contractual Term (Years) |  | Weighted Average Grant Date Fair Value |  | Weighted Average Intrinsic Value
Outstanding – December 31, 2022 |  | 1,844,781 |  | $ | 9.84 |  | 1.39 |  | $ | 1.36 |  | $ | —
Granted |  | — |  |  | — |  | — |  |  | — |  |  | —
Exercised |  | — |  |  | — |  | — |  |  | — |  |  | —
Expired |  | — |  |  | — |  | — |  |  | — |  |  | —
Outstanding – December 31, 2023 |  | 1,844,781 |  |  | 9.84 |  | 0.55 |  |  | 1.36 |  |  | —
Exercisable – December 31, 2023 |  | 1,844,781 |  |  | 9.84 |  | 0.55 |  |  | 1.36 |  |  | —
Non-exercisable – December 31, 2023 |  | — |  | $ | — |  | — |  | $ | — |  | $ | —

X
- Definition Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration